Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
| Business Activity | PASS |
| Debt Ratio (0.26%) | PASS |
| Cash Ratio (0.23%) | PASS |
| Receivables Ratio (0.16%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-16 | 6.20 | Pending | -- |
| 2026-04-22 | 10.81 | 12.58 | +16.4% |
| 2026-01-28 | 3.09 | 3.33 | +7.7% |
| 2025-10-21 | 4.94 | 6.03 | +22.0% |
| 2025-07-17 | 8.92 | 8.84 | -0.9% |
| 2025-04-22 | 11.48 | 11.97 | +4.3% |
| 2025-01-23 | 3.85 | 3.84 | -0.3% |
| 2024-10-17 | 9.65 | 8.37 | -13.3% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $50.2B | $1.8B | — | — | — | 8.12 |
| 2025-12-31 | $49.7B | $547.0M | — | — | — | 2.48 |
| 2025-09-30 | $50.7B | $1.2B | — | — | — | 5.35 |
| 2025-06-30 | $49.8B | $1.7B | — | — | — | 7.75 |
| 2025-03-31 | $48.9B | $2.2B | — | — | — | 9.67 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-19 | PENCZEK RONALD W | Officer | 1,531 | $450.6K |
| 2026-05-19 | PENCZEK RONALD W | Officer | 1,531 | $617.2K |
| 2026-05-13 | HAY LEWIS III | Director | 563 | -- |
| 2026-05-13 | PERU RAMIRO G | Director | 563 | -- |
| 2026-05-13 | SCHNEIDER RYAN M. | Director | 563 | -- |
| 2026-05-13 | COLLIS STEVEN H | Director | 563 | -- |
| 2026-05-13 | STRABLE-SOETHOUT DEANNA D | Director | 563 | -- |
| 2026-05-13 | DEVORE SUSAN D | Director | 563 | -- |
| 2026-05-13 | NERI ANTONIO F | Director | 563 | -- |
| 2026-05-13 | JALLAL BAHIJA | Director | 563 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 19.9M | $7.8B | 0.1% |
| Vanguard Capital Management LLC | 14.3M | $5.7B | 0.1% |
| State Street Corporation | 10.3M | $4.1B | 0.0% |
| Wellington Management Group, LLP | 8.2M | $3.2B | 0.0% |
| Vanguard Portfolio Management LLC | 6.4M | $2.5B | 0.0% |
| Sanders Capital, LLC | 5.9M | $2.3B | 0.0% |
| Geode Capital Management, LLC | 5.2M | $2.0B | 0.0% |
| Artisan Partners Limited Partnership | 5.1M | $2.0B | 0.0% |
| Invesco Ltd. | 4.8M | $1.9B | 0.0% |
| Harris Associates L.P. | 4.8M | $1.9B | 0.0% |
$80.6B
1.95
0.671
21
$200.4B
$31.8B
-16.8%
1.7%
1.77
2.86
0.0%
96,129
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-16 | $6.20 | Pending | — |
| 2026-04-22 | $10.81 | $12.58 | +16.4% |
| 2026-01-28 | $3.09 | $3.33 | +7.7% |
| 2025-10-21 | $4.94 | $6.03 | +22.0% |
| 2025-07-17 | $8.92 | $8.84 | -0.9% |
| 2025-04-22 | $11.48 | $11.97 | +4.3% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($400.62, 21 analysts) | |||
| 10 | $3,939.70 | +$66.50 (2%) | 0.1R |
| 50 | $19,698.50 | +$332.50 (2%) | 0.1R |
| 100 | $39,397.00 | +$665.00 (2%) | 0.1R |
| To Fair Value ($350.70) | |||
| 10 | $3,939.70 | +$-432.70 (-11%) | -0.7R |
| 50 | $19,698.50 | +$-2,163.50 (-11%) | -0.7R |
| 100 | $39,397.00 | +$-4,327.00 (-11%) | -0.7R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| CNC | 0.612 |
| MOH | 0.575 |
| UNH | 0.555 |
| CVS | 0.484 |
| HUM | 0.478 |
| Ticker | Correlation |
|---|---|
| VIA | -0.154 |
| 5069.KL | -0.122 |
| ZAIN.KW | -0.120 |
| AMC.AX | -0.120 |
| SHWZ | -0.116 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.